Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-human-T-lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s)

NCT00105183 is registered in ClinicalTrials.gov with Neovii Biotech as lead sponsor.

NCT NCT00105183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00105183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-human-T-lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s)
Lead sponsor
Neovii Biotech
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2005
Completion date
January 31, 2011
Enrollment
223 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

bronchiectasis, chronic obstructive pulmonary, cystic fibrosis, idiopathic pulmonary fibrosis, pulmonary vascular disease